Here is Why Growth Investors Should Buy CareTrust REIT (CTRE) Now

Zacks Investment Research highlights CareTrust REIT (CTRE) as a strong growth stock, citing its favorable Growth Score of B and Zacks Rank #2. The company's EPS is projected to grow 20.3% this year, significantly exceeding the industry average of 0.7%, and its year-over-year cash flow growth is 67.6% compared to the industry average of 2.8%. Furthermore, current-year earnings estimates for CareTrust REIT have been revised upward, with the Zacks Consensus Estimate surging 3.1% over the past month.

Analysis

CareTrust REIT (CTRE) is highlighted by Zacks Investment Research as a promising opportunity for growth investors, supported by its proprietary Growth Score of B and a Zacks Rank #2 (Buy). The healthcare real estate investment trust is projected to deliver substantial earnings per share (EPS) growth of 20.3% for the current year, a figure that markedly surpasses the industry average expectation of 0.7%. This strong earnings trajectory is further bolstered by impressive cash flow dynamics; CTRE's year-over-year cash flow growth stands at 67.6%, significantly outperforming the industry's 2.8% average. Moreover, its annualized cash flow growth rate over the past three to five years has been 12.5%, compared to an industry average of 3.1%. Reinforcing this positive outlook, current-year earnings estimates for CTRE have seen upward revisions, with the Zacks Consensus Estimate climbing 3.1% in the past month, a trend empirically correlated with near-term stock price movements.

Key Decisions for Investors

• Investors seeking growth exposure within the healthcare REIT sector might consider CareTrust REIT, given its projected 20.3% EPS growth and 67.6% year-over-year cash flow growth, both substantially exceeding industry benchmarks.
• Monitor future earnings estimate revisions for CTRE, as continued positive revisions could signal sustained upward momentum in line with Zacks' research.
• While CTRE exhibits strong growth indicators, investors should remain cognizant of the inherent volatility and above-average risks typically associated with growth-focused equities, as noted generally for such stocks.